CRISPR-Cas 9 is a gene-editing tool that made it possible to rewrite any organism's genetic code and tackle genetic diseases more effectively. Known as genetic scissors, CRISPR identifies a DNA ...
Earlier in March 2026, CRISPR Therapeutics completed a US$550 million private offering of 1.7308% Convertible Senior ...
Victoria Gray, the first patient treated with CRISPR, and Jennifer Doudna, the CRISPR pioneer, at the 2025 Liberty Science Center's Genius Gala. In a recent conversation with Nobel Prize winning ...
Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results